Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial

Jahr

2017

Autoren

Cadavid D, Balcer L, Galetta S, Aktas O, Ziemssen T, Vanopdenbosch L, Frederiksen J, Skeen M, Jaffe GJ, Butzkueven H, Ziemssen F, Massacesi L, Chai Y, Xu L, Freeman S; RENEW Study Investigators.

Verlag

Lancet Neurol. 2017 Mar;16(3):189-199.

Link

https://doi.org/10.1016/s1474-4422(16)30377-5

Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial

COVID-19 and multiple sclerosis: challenges and lessons for patient care

A future of AI-driven personalized care for people with multiple sclerosis

Comparative efficacy of diroximel fumarate, ozanimod and interferon beta-1a for relapsing multiple sclerosis using matching-adjusted indirect comparisons

Evaluation of therapy satisfaction with cladribine tablets in patients with RMS: Final results of the non-interventional study CLEVER

Change from platform to high efficacy disease-modifying treatment for multiple sclerosis despite NEDA